Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed

Cancer Biology and Therapy

Volumn 8, Issue 9, 2009, Pages 782-791

  Di Gennaro, Elena ^a   Bruzzese, Francesca ^a   Pepe, Stefano ^b   Leone, Alessandra ^a   Delrio, Paolo ^a   Subbarayan, Pochi R ^c   Avallone, Antonio ^a   Budillon, Alfredo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

5 fluorouracil; Colorectal cancer; HDAC inhibitor; p53; Raltitrexed; Thimidilate synthase; Vorinostat

Indexed keywords

FLUOROURACIL; FOLINIC ACID; PROTEIN P53; RALTITREXED; THYMIDYLATE SYNTHASE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; WILD TYPE;

EID: 68149172699     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.9.8118     Document Type: Article

References (46)

1. O'Dwyer PJ, Eckhardt SG, Haller DG, Tepper J, Ahnen D, Hamilton S, et al. Priorities in colorectal cancer research: recommendations from the gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. J Clin Oncol 2007; 25:2313-21.
2. Budillon A, Bruzzese F, Di Gennaro E, Caraglia M. Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug Targets 2005; 6:337-51.
3. Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Recent Patents Anticancer Drug Discov 2007; 2:119-34.
4. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26:1351-6.
5. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265:17174-9.
6. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9:3578-88.
7. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98:2865-8.
8. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-28.
9. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-31.
10. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996; 5:245-53.
11. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003; 4:13-8.
12. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606.
13. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007; 13:2318-22.
14. Lee JH, Park JH, Jung Y, Kim JH, Jong HS, Kim TY, et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by downregulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006; 5:3085-95.
15. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2:151-63.
16. Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 2006.
17. Ackland SP, Clarke SJ, Beale P, Peters GJ. Thymidylate synthase inhibitors. Cancer Chemother Biol Response Modif 2002; 20:1-36.
18. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22:529-36.
19. Ackland S, Clarke S, Beale P, Peters G. Thymidylate synthase inhibitors. Cancer Chemother Biol Response Modif 2006; 1:403-27.
20. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8.
21. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22:3766-75.
22. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51:5579-86.
23. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16:2943-52.
24. Cunningham D, Zalcberg J, Smith I, Gore M, Pazdur R, Burris H, 3rd, et al. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. Ann Oncol 1996; 7:179-82.
25. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, et al. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 1995; 71:914-24.
26. van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999; 5:643-54.
27. Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 2003; 9:792-801.
28. Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, Jackman AL, et al. Comparison of thymidylate synthase (TS) protein upregulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res 2000; 6:2538-46.
29. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587:194-205.
30. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004; 5:341-51.
31. Chu E, Takechi T, Jones KL, Voeller DM, Copur SM, Maley GF, et al. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biol 1995; 15:179-85.
32. Chu E, Copur SM, Ju J, Chen TM, Khleif S, Voeller DM, et al. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 1999; 19:1582-94.
33. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996; 69:190-2.
34. Zheng M, Wang H, Zhang H, Ou Q, Shen B, Li N, et al. The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. J Cancer Res Clin Oncol 1999; 125:357-60.
35. Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007; 96:769-75.
36. Subbarayan P, M S, Nelson G, Shabashvili D, Ardalan B. Akt/PKB pathway is affected in 5-FU resistant HT-29 cells. In: AACR-95th Annual meeting. Orlando, Florida 2004; 987.
37. Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, et al. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFNalpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 2006; 12:617-25.
38. Avallone A, Di Gennaro E, Bruzzese F, Laus G, Delrio P, Caraglia M, et al. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. Anticancer Drugs 2007; 18:781-91.
39. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, et al. Sequencedependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002; 86:819-27.
40. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4:793-805.
41. Menzel T, Schauber J, Kreth F, Kudlich T, Melcher R, Gostner A, et al. Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells. Eur J Cancer Prev 2002; 11:271-81.
42. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005; 65:7386-92.
43. Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002; 21:4595-600.
44. Ju J, Pedersen-Lane J, Maley F, Chu E. Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 1999; 96:3769-74.
45. Lee Y, Chen Y, Chang LS, Johnson LF. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res 1997; 234:270-6.
46. Avallone A, Delrio P, Guida C, Tatangelo F, Petrillo A, Marone P, et al. Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. Br J Cancer 2006; 94:1809-15.